CA 02865715 2014-08-27
1
DESCRIPTION
TRANSDERMAL PATCH
TECHNICAL FIELD
[0001] The present invention relates to a transdermal patch containing
rivastigmine, and
specifically relates to a transdermal patch for the treatment of Alzheimer's
disease including two
layers composed of a rivastigmine-containing layer and an acrylic pressure-
sensitive adhesive
layer.
BACKGROUND ART
[0002] Rivastigmine is one of the acetylcholine esterase inhibitors and
is used as a
therapeutic agent for Alzheimer's dementia (anti-dementia drug).
For such an anti-dementia drug, oral administration such as a tablet, a
capsule, syrup, and
granules, and administration by injection or through the rectum have been
studied depending on
a medicinal agent or a disease condition. In recent years, transdermal
administration, that is,
administration using a transdermal patch has also been developed for such an
anti-dementia drug.
[0003] It is considered that the rivastigmine is relatively easily
oxidized, and it is
indicated that decomposition products of the rivastigmine may increase with
time. To address
this, a technique of adding an anti-oxidizing agent into a transdermal patch
containing the
rivastigmine has been developed (for example, Patent Document 1 and Patent
Document 2).
Patent Document 2 discloses a preparation in which a storage layer containing
the rivastigmine is
laminated to a silicone pressure-sensitive adhesive. However, the silicone
pressure-sensitive
CA 02865715 2014-08-27
2
adhesive itself is expensive and a release liner for such a silicone pressure-
sensitive adhesive
needs special treatment. Hence, the preparation has a problem of high cost.
Each transdermal patch disclosed in Patent Document 1 and Patent Document 2
uses an
acrylic pressure-sensitive adhesive containing a carboxy group. However, the
use of such an
acrylic pressure-sensitive adhesive is considered to affect the oxidation of
the rivastigmine to not
a little extent. To address this, there is a report that the use of a pressure-
sensitive adhesive
having no carboxy group and no hydroxy group as the acrylic pressure-sensitive
adhesive
enables the formation of a transdermal patch excellent in temporal stability
of the rivastigmine
(Patent Document 3).
[0004] In order to improve skin permeability of the rivastigmine or to
reduce skin
irritation caused by a pressure-sensitive adhesive layer, a transdermal patch
using a hydroxy
group-containing acrylate-rubber hybrid pressure-sensitive adhesive (Patent
Document 4) and a
transdermal patch including an acrylic pressure-sensitive adhesive layer that
has a hydroxy group,
etc. and that contains a nonvolatile substance such as citric acid in order to
reduce the loss of an
active substance (medicinal agent) due to vaporization in the production
process (Patent
Document 5) have been developed. However, there is no discussion on the
stability of the
rivastigmine in these documents.
Related Art Documents
Patent Documents
[0005] Patent Document 1: Japanese Translation of PCT International
Application
Publication No. JP-T-2002-500178
Patent Document 2: Japanese Translation of PCT International Application
Publication No.
JP-T-2009-517468
Patent Document 3: International Publication WO 2011/076621 pamphlet
Patent Document 4: U.S. Patent Application Publication No. 2011/0066120
specification
CA 02865715 2014-08-27
3
Patent Document 5: European Patent No. 2172194 specification
Patent Document 6: Japanese Translation of PCT International Application
Publication No.
JP-T-9-503756
Non-Patent Document
Non-Patent Document 1: JYTTE ROED-PERERSEN et al.: Contact dermatitis from
antioxidants HIDDEN SENSITIZERS IN TOPICAL MEDICATIONS AND FOODS, British
Journal of Dermatology (1976) 94, 233.
SUMMARY OF THE INVENTION
Problem to be Solved by the Invention
[0006] As described above, in order to solve the temporal instability of the
rivastigmine due
to oxidation, the addition of an anti-oxidizing agent and the use of a
pressure-sensitive adhesive
having no carboxy group and no hydroxy group have been developed. Thus, in a
transdermal
patch using an acrylic pressure-sensitive adhesive containing a hydroxy group,
the skin
permeability of the rivastigmine must be improved. Also, the stability of the
rivastigmine must
be improved in another manner because the pressure-sensitive adhesive layer
used is considered
to be unfavorable from the viewpoint of oxidation stability. There is another
demand for a
transdermal patch containing no anti-oxidizing agent, because adding an anti-
oxidizing agent
may cause skin irritation (Non-Patent Document 1).
[0007] In the production of a conventional transdermal patch containing the
rivastigmine, a
layer containing the medicinal agent and a pressure-sensitive adhesive is
typically formed by a
spread coating method (a production method including forming a layer
containing a medicinal
agent and a pressure-sensitive adhesive by coating followed by a heating and
drying process).
However, in the spread coating method, an additive for inhibiting the
vaporization of a medicinal
CA 02865715 2014-08-27
4
agent is added as described in Patent Document 5, a coating is dried at a
drying temperature of
60 C or higher (for example, Patent Document 4 and Patent Document 5), or a
medicinal agent is
added to a pressure-sensitive adhesive layer in an amount that is a certain
amount more than
necessary in advance, that is, "excess addition" is performed, on the
assumption that the
medicinal agent is volatilized during production. Such a method doest not
consider the effect of
the "heating" (oxidation, etc.) during the production process of a transdermal
patch. Therefore,
there is a room for improvement in the production method of the transdermal
patch for
improving the temporal stability of the rivastigmine.
[0008] The present inventors provide a transdermal patch containing the
rivastigmine,
which allows desired adhesive properties to be thoroughly obtained as well as
has good temporal
stability of the rivastigmine without using an anti-oxidizing agent. In
addition, the transdermal
patch can be produced easily and with reduced cost.
Means for Solving the Problem
[0009] The present inventors have carried out intensive studies in order to
solve the
problems described above and have studied the structure of a transdermal patch
having excellent
temporal stability of the rivastigmine without using an anti-oxidizing agent.
The present
inventors have searched the structure of a transdermal patch that can be
produced by a so-called
"ointment coating method" while avoiding a heating process that may impair the
stability of the
rivastigmine, as much as possible. As a result, the present inventors have
developed a structure
in which a medicinal agent-containing layer and a pressure-sensitive adhesive-
containing layer
are separated, that is, a two-layer structure composed of a rivastigmine-
containing layer and a
pressure-sensitive adhesive layer including a particular acrylic pressure-
sensitive adhesive on a
backing, and have found that the structure can solve the problems, and the
present invention has
been accomplished.
[0010] That is, the present invention relates to a transdermal patch for the
treatment of
CA 02865715 2014-08-27
Alzheimer's disease. The transdermal patch includes a backing, a rivastigmine-
containing layer
provided on the backing, a pressure-sensitive adhesive layer provided on the
rivastigmine-containing layer, and a release liner; or includes a backing, a
pressure-sensitive
adhesive layer provided on the backing, a rivastigmine-containing layer
provided on the
pressure-sensitive adhesive layer, and a release liner. In the transdermal
patch, the
rivastigmine-containing layer contains rivastigmine and an alkyl
(meth)acrylate resin, the
pressure-sensitive adhesive layer is composed of an acrylic pressure-sensitive
adhesive
containing a (meth)acrylic acid ester having a hydroxy group, and neither the
rivastigmine-containing layer nor the pressure-sensitive adhesive layer
contains an anti-oxidizing
agent.
[0011] The present invention further provides embodiments below.
1. In the transdermal patch for the treatment of Alzheimer's disease, the
rivastigmine-containing
layer is a layer formed by using a solution containing the rivastigmine under
a condition at 1 C
or higher and lower than 60 C.
2. In the transdermal patch for the treatment of Alzheimer's disease, the
rivastigmine-containing
layer contains the rivastigmine in an amount of 20% to 95% by mass based on a
total mass of the
layer.
3. In the transdermal patch for the treatment of Alzheimer's disease, the
rivastigmine-containing
layer is a layer having a thickness of 10 pm to 80 rn and the pressure-
sensitive adhesive layer is
a layer having a thickness of 10 lAm to 100 pm.
[0012] The present invention also relates to a method for producing a
transdermal patch for
the treatment of Alzheimer's disease. The method includes i) a rivastigmine
layer formation
step of applying a solution containing rivastigmine onto a backing to form a
rivastigmine-containing layer, a pressure-sensitive adhesive layer formation
step of applying a
solution containing an acrylic pressure-sensitive adhesive onto a release
liner to form a
pressure-sensitive adhesive layer, and a transdermal patch formation step of
bonding the
CA 02865715 2014-08-27
6
rivastigmine-containing layer formed on the backing to the pressure-sensitive
adhesive layer
formed on the release liner, includes ii) a pressure-sensitive adhesive layer
formation step of
applying a solution containing an acrylic pressure-sensitive adhesive onto a
backing to form a
pressure-sensitive adhesive layer, a rivastigmine layer formation step of
applying a solution
containing rivastigmine onto a release liner to form a rivastigmine-containing
layer, and a
transdermal patch formation step of laminating the pressure-sensitive adhesive
layer formed on
the backing to the rivastigmine-containing layer formed on the release liner,
or includes iii) a
pressure-sensitive adhesive layer formation step of applying a solution
containing an acrylic
pressure-sensitive adhesive onto a backing to form a pressure-sensitive
adhesive layer, a
rivastigmine layer formation step of applying a solution containing
rivastigmine onto the
pressure-sensitive adhesive layer to form a rivastigmine-containing layer, and
a transdermal
patch formation step of laminating the rivastigmine-containing layer formed on
the
pressure-sensitive adhesive layer on the backing to a release liner. In the
method, the solution
containing rivastigmine contains the rivastigmine and an alkyl (meth)acrylate
resin, the solution
containing an acrylic pressure-sensitive adhesive contains an acrylic pressure-
sensitive adhesive
containing a (meth)acrylic acid ester having a hydroxy group, and neither the
solution containing
rivastigmine nor the solution containing an acrylic pressure-sensitive
adhesive contains an
anti-oxidizing agent.
[0013] The present invention further provides embodiments below.
4. In the method, the rivastigmine-containing layer formation step includes
applying the solution
containing rivastigmine onto the backing under a temperature condition of 1 C
or higher and
lower than 60 C.
5. The method further includes a cooling step of allowing the pressure-
sensitive adhesive layer to
cool or forced-cooling the pressure-sensitive adhesive layer, after the
pressure-sensitive adhesive
layer formation step and before the transdermal patch formation step.
6. The method further includes an aging step before and after the cooling
step.
CA 02865715 2014-08-27
7
[0014] The present invention further relates to a product of a transdermal
patch for the
treatment of Alzheimer's disease produced by sealing the transdermal patch for
the treatment of
Alzheimer's disease or a transdermal patch for the treatment of Alzheimer's
disease produced by
the method in a package composed of a laminate of multi-layered films or multi-
layered sheets.
The transdermal patch product has aspects below.
6. In the transdermal patch product, an innermost layer of the package is a
layer containing
polyacrylonitrile as a main component.
7. In the transdermal patch product, the package includes a film or a sheet
having a layer
containing an oxygen absorber or an oxygen absorber is separately enclosed in
the package.
8. In the transdermal patch product, an atmosphere in the package is
substituted and filled with
nitrogen.
[0015] The present invention also relates to a transdermal patch for the
treatment of
Alzheimer's disease that includes a polyester film backing, a rivastigmine-
containing layer
provided on the backing, a pressure-sensitive adhesive layer provided on the
rivastigmine-containing layer, and a release liner. In the transdermal patch,
the
rivastigmine-containing layer contains rivastigmine and an alkyl
(meth)acrylate resin, the
pressure-sensitive adhesive layer includes an acrylic pressure-sensitive
adhesive containing a
(meth)acrylic acid ester having a hydroxy group, neither the rivastigmine-
containing layer nor
the pressure-sensitive adhesive layer contains an anti-oxidizing agent or an
acrylic
pressure-sensitive adhesive containing a (meth)acrylic acid ester having a
carboxy group, and the
transdermal patch includes a degradation product of the rivastigmine in a
total amount of less
than 0.50% by mass based on an amount of the rivastigmine after storage under
a severe
condition (60 C) for two weeks from a production date of the transdermal
patch.
Effect of the Invention
[0016] The present invention can provide a transdermal patch that has
excellent practical
CA 02865715 2014-08-27
8
performance. The transdermal patch is configured by providing two layers,
i.e., a
rivastigmine-containing layer and a pressure-sensitive adhesive layer having
an acrylic
pressure-sensitive adhesive, on a backing. Thus, even without using an anti-
oxidizing agent
and even when an acrylic pressure-sensitive adhesive containing a hydroxy
group that may affect
the oxidation of the rivastigmine is used as the pressure-sensitive adhesive,
the transdermal patch
can suppress the formation of degradation products of the rivastigmine after
the production of the
transdermal patch, has excellent temporal stability of the rivastigmine, and
has adhesive
properties required for a transdermal patch.
The addition of the alkyl (meth)acrylate resin into the rivastigmine-
containing layer enables
the formation of a rivastigmine-containing layer having excellent adhesive
properties to the
backing and excellent attaching properties to a skin. The use of the acrylic
pressure-sensitive
adhesive containing a (meth)acrylic acid ester having a hydroxy group as the
pressure-sensitive
adhesive enables the formation of a pressure-sensitive adhesive layer having
excellent attaching
properties to a skin and excellent adhesive properties to the backing.
The use of the rivastigmine-containing layer formed at a certain temperature
or lower can
provide a transdermal patch eliminating the oxidation effect on the
rivastigmine due to
temperature.
[0017] The production method of the present invention does not require a
heating and
stirring process or a heating and drying process, or the like for the
formation of the
rivastigmine-containing layer. With this method, it is possible to produce a
transdermal patch
while eliminating high temperature heating processes that can affect the
oxidation of the
rivastigmine as many as possible during the production of the transdermal
patch.
Therefore, in the obtained transdermal patch, the formation of rivastigmine
degradation
products due to heat is suppressed during the production of the transdermal
patch, and the
method enables the formation of a transdermal patch having excellent stability
of the
rivastigmine.
CA 02865715 2014-08-27
9
In addition, the transdermal patch of the present invention does not need
"excess addition",
that is, adding a medicinal agent in an amount that is a certain amount more
than necessary in
advance, and does not include an anti-oxidizing agent, which enables cost
reduction.
MODES FOR CARRYING OUT THE INVENTION
[0018] The transdermal patch for the treatment of Alzheimer's disease of
the present
invention is composed of a backing, a rivastigmine-containing layer, a
pressure-sensitive
adhesive layer, and a release liner, and is characterized in that neither the
rivastigmine-containing
layer nor the pressure-sensitive adhesive layer contains any anti-oxidizing
agent.
The transdermal patch of the present invention has a specific structure
composed of the
rivastigmine-containing layer provided on the backing, the pressure-sensitive
adhesive layer
provided on the rivastigmine-containing layer, and the release liner or a
specific structure
composed of the backing, the pressure-sensitive adhesive layer provided on the
backing, the
rivastigmine-containing layer provided on the pressure-sensitive adhesive
layer, and the release
liner.
[0019] [Rivastigmine-Containing Layer]
In the transdermal patch of the present invention, the rivastigmine-containing
layer contains
rivastigmine and an alkyl (meth)acrylate resin.
[0020] The rivastigmine
((S)-N-ethyl-3-[1-(dimethylamino)ethy1]-N-methyl-phenyl-carbamate) used in the
present
invention may be either in a free base form or in an acid addition salt form.
The amount of the rivastigmine contained is not particularly limited, but is,
for example,
20% to 95% by mass, preferably 30% to 90% by mass, and more preferably 35% to
90% by
mass, based on the total mass of the rivastigmine-containing layer.
The amount of the rivastigmine contained is, for example, 10% to 40% by mass,
preferably
CA 02865715 2014-08-27
10% to 35% by mass, and more preferably 10% to 25% by mass, based on the total
mass of the
rivastigmine-containing layer and the pressure-sensitive adhesive layer
described later.
[0021] The alkyl (meth)acrylate resin contained in the rivastigmine-
containing layer
works as a thickener and includes alkyl (meth)acrylate copolymers and acrylic
pressure-sensitive
adhesives containing a (meth)acrylic acid ester.
[0022] Specific examples of the alkyl (meth)acrylate copolymer include a
methyl
methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate copolymer, a
methacrylic
acid-methyl methacrylate copolymer, a methacrylic acid-ethyl acrylate
copolymer, an ethyl
acrylate-methyl methacrylate copolymer, and a butyl methacrylate-methyl
methacrylate
copolymer. The weight average molecular weight of the alkyl (meth)acrylate
copolymer is not
particularly limited, but is 10,000 to 300,000 and preferably 100,000 to
200,000.
For such a copolymer, a commercial product may be appropriately used, and for
example,
Eudragit (registered trademark, manufactured by Evonik Rohm GmbH) products can
be suitably
used. Specific examples of the commercial product include Eudragit E 100,
Eudragit EPO,
Eudragit Li 00, Eudragit L100-55, Eudragit S100, Eudragit RL100, Eudragit
RLPO, Eudragit
RS100, Eudragit RSPO, and Plastoid B.
Among these Eudragit products, Eudragit EPO is especially preferred from the
viewpoints
of miscibility with the rivastigmine and adhesive properties to a backing.
[0023] Specifically, the acrylic pressure-sensitive adhesive containing
a (meth)acrylic
acid ester is preferably a polymer obtained by copolymerization of one or more
alkyl esters of
(meth)acrylic acid as main monomer components with one or more optional
copolymerizable
monomers (for example, 2-ethylhexyl acrylate, vinylpyrrolidone, vinyl acetate,
methoxyethyl
acrylate, hydroxyethyl acrylate, and acrylic acid). Here, examples of the
alkyl (meth)acrylate
include alkyl acrylates such as methyl acrylate, ethyl acrylate, isopropyl
acrylate, n-butyl acrylate,
t-butyl acrylate, isoamyl acrylate, 2-ethylhexyl acrylate, n-octyl acrylate,
isooctyl acrylate,
isononyl acrylate, decyl acrylate, and dodecyl acrylate; and alkyl
methacrylates such as methyl
CA 02865715 2014-08-27
11
methacrylate, ethyl methacrylate, n-butyl methacrylate, isobutyl methacrylate,
t-butyl
methacrylate, isoamyl methacrylate, 2-ethylhexyl methacrylate, n-octyl
methacrylate, isooctyl
methacrylate, isononyl methacrylate, decyl methacrylate, and dodecyl
methacrylate. These
alkyl (meth)acrylates may be used singly or in combination of two or more of
them. For
example, n-butyl acrylate may be used in combination with methyl methacrylate.
The weight
average molecular weight of the (meth)acrylic acid ester used for the acrylic
pressure-sensitive
adhesive containing a (meth)acrylic acid ester is not particularly limited,
but is 100,000 to
1,000,000.
It is preferable that the acrylic pressure-sensitive adhesive containing a
(meth)acrylic acid
ester do not substantially include a component containing both a hydroxy group
and a carboxy
group. Even when the acrylic pressure-sensitive adhesive includes the
component containing
both a hydroxy group and a carboxy group, the component is preferably included
in an amount
of 5% by mass or less based on the total mass of the acrylic pressure-
sensitive adhesive.
[0024]
The amount of the alkyl (meth)acrylate resin included is not particularly
limited.
In the case of the alkyl (meth)acrylate copolymer, the amount is, for example,
5% to 25% by
mass, preferably 5% to 20% by mass, and more preferably 5% to 15% by mass,
based on the
total mass of the rivastigmine-containing layer. In the case of the acrylic
pressure-sensitive
adhesive containing a (meth)acrylic acid ester, the amount is, for example,
20% to 90% by mass,
preferably 30% to 85% by mass, and more preferably 40% to 80% by mass, based
on the total
mass of the rivastigmine-containing layer.
Based on the total mass of the rivastigmine-containing layer and the pressure-
sensitive
adhesive layer described later, in the case of the alkyl (meth)acrylate
copolymer, the amount of
the alkyl (meth)acrylate resin included is, for example, 0.5% to 5.0% by mass,
preferably 1.0%
to 4.0% by mass, and more preferably 1.0% to 3.0% by mass. In the case of the
acrylic
pressure-sensitive adhesive containing the (meth)acrylic acid ester, the
amount is, for example,
40% to 90% by mass, preferably 50% to 90% by mass, and more preferably 60% to
90% by
CA 02865715 2014-08-27
12
mass.
[0025] In the present invention, the rivastigmine-containing layer may
further include
an additional additive such as a softener (plasticizer) and an inorganic
filler, if desired.
When the additional additive is included, the amount thereof is, for example,
0% to 30% by
mass and preferably 0% to 20% by mass based on the total mass of the
rivastigmine-containing
layer. The amount of the additional additive included is, for example 0% to
20% by mass and
preferably 0% to 10% by mass based on the total mass of the rivastigmine-
containing layer and
the pressure-sensitive adhesive layer described later.
[0026] [Pressure-Sensitive Adhesive Layer]
The pressure-sensitive adhesive layer used in the transdermal patch of the
present invention
is composed of an acrylic pressure-sensitive adhesive containing a
(meth)acrylic acid ester
having a hydroxy group.
[0027] Specifically, the acrylic pressure-sensitive adhesive is
preferably a polymer
obtained by copolymerization of one or more hydroxyalkyl esters of
(meth)acrylic acid with one
or more optional copolymerizable monomers (for example, 2-ethylhexyl acrylate,
vinylpyrrolidone, vinyl acetate, methoxyethyl acrylate, hydroxyethyl acrylate,
and acrylic acid).
Here, examples of the hydroxyalkyl (meth)acrylate include an ester obtained
from a
hydroxy group-containing primary to tertiary alcohol having a C2_18 alkyl
group and acrylic acid
or methacrylic acid. Specific examples of the hydroxyalkyl (meth)acrylate
include
2-hydroxyethyl acrylate, 2-hydroxypropyl acrylate, 3-hydroxypropyl acrylate, 4-
hydroxybutyl
acrylate, 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, 3-
hydroxypropyl
methacrylate, and 4-hydroxybutyl methacrylate.
As the acrylic pressure-sensitive adhesive containing the acrylic acid ester
having a
hydroxy group, a commercial product such as DURO-TAK (registered trademark) 87-
202A,
DURO-TAK 87-208A, DURO-TAK 87-2510, DURO-TAK 87-208A, DURO-TAK 87-2287,
DURO-TAK 87-4287, DURO-TAK 87-2516, and DURO-TAK 87-2525 (Henkel) may be
CA 02865715 2014-08-27
13
suitably used.
It is preferable that the pressure-sensitive adhesive layer do not
substantially include an
acrylic pressure-sensitive adhesive containing a carboxy group as the acrylic
pressure-sensitive
adhesive. Even when the layer includes the acrylic pressure-sensitive adhesive
containing a
carboxy group, the acrylic pressure-sensitive adhesive containing a carboxy
group is preferably
included in an amount of 5% by mass or less based on the total mass of the
pressure-sensitive
adhesive layer.
In the present invention, the mass ratio of the pressure-sensitive adhesive
layer is, for
example, 40% to 95% by mass, preferably 50% to 90% by mass, and more
preferably 60% to
90% by mass, in the total mass of the rivastigmine-containing layer above and
the
pressure-sensitive adhesive layer.
[0028] In the present invention, the pressure-sensitive adhesive layer
may further
include an additional additive such as an additional medicinal agent, a
tackifier, a cross-linking
agent, a softener (plasticizer), an absorption enhancer, polyhydric alcohols,
silicone oils, an
inorganic filler, and an ultraviolet absorber.
Examples of the tackifier include terpene tackifiers, terpene phenol
tackifiers, coumarone
indene tackifiers, styrene tackifiers, rosin tackifiers, xylene tackifiers,
phenol tackifiers, and
petroleum tackifiers.
Various cross-linking agents may be further added into the pressure-sensitive
adhesive layer
in order to increase a cohesive power of the acrylic pressure-sensitive
adhesive. Examples of
the cross-linking agent include multifunctional isocyanate compounds,
multifunctional epoxy
compounds, and polyvalent metal salts. Polyisocyanates [for example, CORONATE
(registered
trademark) HL (hexamethylene diisocyanate HDI-TMP adduct, manufactured by
Nippon
Polyurethane Industry Co., Ltd.)] is specifically preferred. Usable examples
of the filler
include calcium carbonate, magnesium carbonate, silicates, zinc oxide,
titanium oxide,
magnesium sulfate, and calcium sulfate.
CA 02865715 2014-08-27
14
Examples of the absorption enhancer include terpene oils such as d-limonene;
fatty acid
esters such as glycerin monolaurate, glycerin monooleate, and diethyl
sebacate; and fatty acids
such as Azone, Pirotiodecane, oleic acid, lauric acid, and myristic acid and
derivatives of them.
These additives are optionally added. The amount of the additional additive
is, for
example 0% to 40% by mass and preferably 0% to 30% mass based on the total
mass of the
pressure-sensitive adhesive layer and the rivastigmine-containing layer above.
[0029] [Backing]
Examples of the backing used in the transdermal patch of the present invention
include
flexible backings such as films, nonwoven fabrics, Japanese papers, cotton
fabrics, knitted
fabrics, woven fabrics, and laminated composite bodies of a nonwoven fabric
and a film. Such
a backing is preferably composed of a soft material that can be in close
contact with a skin and
can follow skin movement and of a material that can suppress skin rash and
other trouble after
the transdermal patch is attached for a long time. Examples of the backing
material include a
material containing, as an essential component, polyethylene, polypropylene,
polyethylene
terephthalate, polybutylene terephthalate, polyethylene naphthalate,
polystyrene, nylon, cotton,
acetate rayon, rayon, a rayon/polyethylene terephthalate composite body,
polyacrylonitrile,
polyvinyl alcohol, acrylic polyurethane, ester polyurethane, ether
polyurethane, a
styrene-isoprene-styrene copolymer, a styrene-butadiene-styrene copolymer, a
styrene-ethylene-propylene-styrene copolymer, styrene-butadiene rubber, an
ethylene-vinyl
acetate copolymer, or cellophane, for example.
A preferred backing does not adsorb a medicinal agent and does not release a
medicinal
agent (rivastigmine). In order to suppress the adsorption and release of the
medicinal agent, to
improve transdermal absorbability of the medicinal agent, and to suppress skin
rash and other
trouble, the backing preferably includes one or more layers composed of the
material above and
has a water vapor permeability in a certain range. Specifically, the backing
preferably has a
water vapor permeability (measured at 40 C and 90% RH in accordance with JIS
Z0208) of 300
CA 02865715 2014-08-27
g/m2 24 hr or less and particularly 50 g/m2.24 hr or less. The use of a
backing having a water
vapor permeability within the range can increase skin permeability of the
rivastigmine and can
ensure a suitable water vapor permeability for suppressing skin rash and other
trouble.
In order to make the transdermal patch inconspicuous when it is attached, that
is, in order to
make it easy to show the skin color beneath the patch through it, a plastic
film having excellent
transparency is preferably employed. A backing such as fabrics can obtain
color that is a little
different from skin color by coloring the backing with a coloring agent into a
color tone such as a
flesh color.
The backing typically has a thickness of about 5 lAm to 1 mm. A fabric backing
preferably
has a thickness of 50 vim to 1 mm, more preferably 100 [tm to 800 pm, and even
more preferably
200 [tm to 700 p.m. A plastic film backing preferably has a thickness of 10 tm
to 300[1m,
more preferably 12 1,,trn to 200 jArn, and even more preferably 15 iiM to 150
i_tm. A backing
having a very small thickness of about 5 pn to 30 iiM is preferably provided
with a releasable
carrier film layer on a face opposite to the pressure-sensitive adhesive layer
or to the
rivastigmine-containing layer that is formed on the backing because handling
properties as the
transdermal patch is improved. A backing having a thickness of less than 51AM
reduces the
strength and the handling properties of the transdermal patch, makes
attachment to a skin
difficult, and may be torn due to the contact with another member, for
example, or be peeled off
from a skin within a short period due to the contact with water in a bath, for
example. A
transdermal patch including a backing having an excessively large thickness
(more than 1 mm)
does not easily follow skin movement and readily form a trigger for peeling-
off at the periphery
of the transdermal patch. Hence, such a transdermal patch may be peeled off
from a skin within
a short period or may increase uncomfortable feeling during attachment. In the
case of a film
backing, one side or both sides of the backing may be subjected to a treatment
such as a
sandblast treatment and a corona treatment in order to improve anchoring
properties between the
pressure-sensitive adhesive and the backing. Furthermore, in order to readily
take out the
CA 02865715 2014-08-27
16
transdermal patch from a package, one side or both sides of the backing may be
provided with an
uneven surface by a method other than the sandblast.
As a backing meeting the conditions such as the water vapor permeability, the
transparency,
and the thickness, polyester films are preferred and polyethylene
terephthalate films are
especially preferred.
[0030] [Release Liner]
The release liner used in the transdermal patch of the present invention is
preferably
composed of a material that is unlikely to absorb and adsorb a medicinal
agent, for example, in
the pressure-sensitive adhesive. Examples of such a material include a
polyester film having
one side or both sides treated with silicone, a polyethylene laminated high-
quality paper treated
with silicone, and a glassine paper treated with silicone. The release liner
may have an uneven
surface in order to easily take out the transdermal patch from a package. The
release liner may
have, for example, a rectangular shape with rounded corners and a circular
shape and has the
same size as or a size slightly larger than the size of the backing on which
the
rivastigmine-containing layer and the pressure-sensitive adhesive layer are
provided.
[0031] [Method for Producing Transdermal Patch]
The transdermal patch for the treatment of Alzheimer's disease of the present
invention can
be produced through the steps described in i) or ii) below.
i) A rivastigmine layer formation step of applying a solution containing
rivastigmine onto a
backing to form a rivastigmine-containing layer, a pressure-sensitive adhesive
layer formation
step of applying a solution containing an acrylic pressure-sensitive adhesive
onto a release liner
to form a pressure-sensitive adhesive layer, and a transdermal patch formation
step of laminating
the rivastigmine-containing layer formed on the backing to the pressure-
sensitive adhesive layer
formed on the release liner.
ii) A pressure-sensitive adhesive layer formation step of applying a solution
containing an acrylic
pressure-sensitive adhesive onto a backing to form a pressure-sensitive
adhesive layer, a
CA 02865715 2014-08-27
17
rivastigmine layer formation step of applying a solution containing
rivastigmine onto a release
liner to form a rivastigmine-containing layer, and a transdermal patch
formation step of
laminating the pressure-sensitive adhesive layer formed on the backing to the
rivastigmine-containing layer formed on the release liner.
Alternatively, the transdermal patch of the present invention can also be
produced, for
example, through the steps described in iii) below.
iii) A pressure-sensitive adhesive layer formation step of applying a solution
containing an
acrylic pressure-sensitive adhesive onto a backing to form a pressure-
sensitive adhesive layer, a
rivastigmine layer formation step of applying a solution containing
rivastigmine onto the
pressure-sensitive adhesive layer to form a rivastigmine-containing layer, and
a transdermal
patch formation step of laminating the rivastigmine-containing layer formed on
the
pressure-sensitive adhesive layer on the backing to a release liner.
[0032] The solution containing rivastigmine is a solution containing
rivastigmine and
an alkyl (meth)acrylate resin. Examples of the alkyl (meth)acrylate resin
include the alkyl
(meth)acrylate copolymers and the acrylic pressure-sensitive adhesives
containing a
(meth)acrylic acid ester exemplified above. The solution may further include
an additional
additive such as a softener (plasticizer) and an inorganic filler.
The solution containing an acrylic pressure-sensitive adhesive contains an
acrylic
pressure-sensitive adhesive containing a (meth)acrylic acid ester having a
hydroxy group.
Examples of the pressure-sensitive adhesive include the various pressure-
sensitive adhesives
exemplified above. The solution may further include an additional additive
such as another
medical agent, a tackifier, a cross-linking agent, a softener (plasticizer),
an absorption enhancer,
polyhydrie alcohols, silicone oils, an inorganic filler, and an ultraviolet
absorber.
Each of the solution containing rivastigmine and the solution containing an
acrylic
pressure-sensitive adhesive may appropriately include a solvent or the like,
considering the
operability when such a solution is applied onto the backing, the release
liner, and the like. The
CA 02865715 2014-08-27
18
solvent is not particularly limited as long as the acrylic pressure-sensitive
adhesive containing a
(meth)acrylic acid ester having a hydroxy group, the rivastigmine, and the
alkyl (meth)acrylate
resin can be dissolved.
Each of the solution containing rivastigmine and the solution containing an
acrylic
pressure-sensitive adhesive does not contain an anti-oxidizing agent.
[0033] The method for producing a transdermal patch of the present
invention is
performed, for example, in the procedure below in the case of the process i).
The acrylic pressure-sensitive adhesive containing a (meth)acrylic acid ester
having a
hydroxy group, and additional components except the medical agent and a
solvent (ethyl acetate,
ethanol, and hexane, etc.) for dissolving the pressure-sensitive adhesive, if
desired, are stirred
and mixed at a maximum temperature of room temperature to about 40 C so as to
prepare a
pressure-sensitive adhesive solution homogeneously containing the components.
The prepared
solution is spread on a release liner or a backing with a coater so as to give
a thickness of 10 m
to 100 [im after drying the solvent, and then dried at a temperature of 60 C
to 120 C to form a
pressure-sensitive adhesive layer.
Separately, the rivastigmine, the alkyl (meth)acrylate resin, and additional
components, if
desired, are mixed at a maximum temperature of room temperature or 1 C or
higher and lower
than 60 C to prepare a rivastigmine-containing solution homogeneously
containing the
components. The prepared solution is spread on a release liner or a backing
with a coater so as
to give a thickness of 10 pm to 80 pm to form a rivastigmine-containing layer.
When an acrylic
pressure-sensitive adhesive is used as the alkyl (meth)acrylate resin, a
solvent drying step may be
included after the spread on the release liner or the backing.
Finally, the pressure-sensitive adhesive layer formed on the release liner or
the backing and
the rivastigmine-containing layer formed on the backing or the release liner
are opposed and
laminated to each other, followed by cutting to produce a transdermal patch
having two layers
composed of the pressure-sensitive adhesive layer containing the acrylic
pressure-sensitive
CA 02865715 2014-08-27
19
adhesive and the rivastigmine-containing layer.
[0034] In the transdermal patch of the present invention, from the
viewpoint of the
stability of the rivastigmine as the active component, it is preferred that
the rivastigmine layer
formation step described above is performed by a so-called "ointment coating
method" in which
a mixing step and a drying step are performed at a temperature as low as
possible, rather than a
calendering method or a hot melting method that is employed for a common
transdermal patch
production and that includes a heating and kneading (stirring) step or a
spread coating method
that includes a heating and drying step after coating.
In the present specification, the "ointment coating method" is a method of
forming a layer
at a low temperature, for example, at a temperature of 1 C or higher and lower
than 60 C,
preferably under a temperature condition of 20 C to 34 C, and more preferably
26 C to 34 C.
In other words, in the present invention, the "ointment coating method" means
a method of
forming the rivastigmine-containing layer under the temperature condition
mentioned above by
coating or lamination. The alkyl (meth)acrylate resin in the rivastigmine-
containing layer is
preferably an alkyl (meth)acrylate copolymer having a weight average molecular
weight of
300,000 or less because the coating can be performed at a lower temperature.
[0035] In the transdermal patch of the present invention, the pressure-
sensitive adhesive
layer formation step can be performed by any conventional methods for forming
a
pressure-sensitive adhesive layer such as a spread coating method, an emulsion
method, a hot
melting method, and an electron beam curing method. That is, in the present
invention, the
pressure-sensitive adhesive layer formation step means a step of kneading,
stirring, curing, and
drying a pressure-sensitive adhesive and the like at a high temperature (for
example 60 C to
180 C) to form a pressure-sensitive adhesive layer on a backing or a release
liner.
[0036] Preferably, the method for producing a transdermal patch of the
present
invention further includes a cooling step of allowing the pressure-sensitive
adhesive layer to cool
or forced-cooling the pressure-sensitive adhesive layer, after the pressure-
sensitive adhesive
CA 02865715 2014-08-27
layer formation step and before the transdermal patch formation step. In other
words, it is
preferable that a transdermal patch formation step in which the pressure-
sensitive adhesive layer
is directly brought into contact with the rivastigmine layer be not performed
immediately after
the formation of the pressure-sensitive adhesive layer but the transdermal
patch formation step
be performed after cooling the pressure-sensitive adhesive layer.
The reason for this is as follows. The pressure-sensitive adhesive layer
formation step is
performed at a high temperature. Accordingly, the pressure-sensitive adhesive
layer has a very
high temperature immediately after the formation of the pressure-sensitive
adhesive layer.
When such a pressure-sensitive adhesive layer is directly brought into contact
with the
rivastigmine-containing layer, the rivastigmine layer is heated to so that the
temperature of the
layer increases, which may affect the stability of the rivastigmine.
Therefore, in the present invention, it is preferable that the rivastigmine
layer formation
step and the pressure-sensitive adhesive layer formation step be not performed
in an integrated
system, that is, these steps do not proceed at the same time and are
separately performed (in a
non-integrated system).
[0037] A specific example of the procedure for the non-integrated system
will be
described below.
First, when the pressure-sensitive adhesive layer formation step is performed
by, for
example, a spread coating method, a pressure-sensitive adhesive is diluted
with a solvent such as
toluene, hexane, ethyl acetate, and ethanol and is spread on a backing or a
release liner. The
solvent is evaporated at a high temperature (for example 120 C), and a
pressure-sensitive
adhesive layer is formed on the backing or the release liner. A plurality of
layers containing the
pressure-sensitive adhesive layer and the backing or containing the pressure-
sensitive adhesive
layer and the release liner obtained by the formation step are defined as a
bulk tape. In the bulk
tape, on the assumption that it is left standing for a predetermined period of
time for the
temperature decrease as described later, a release sheet that is removed at
the transdermal patch
CA 02865715 2014-08-27
21
formation step may be laminated on the pressure-sensitive adhesive layer
provided on the
backing or the release liner, in order to suppress drying of the pressure-
sensitive adhesive layer
or to avoid contamination. Examples of the material for the release sheet
include those
exemplified for the release liner above.
After the preparation of the bulk tape, a cooling step of cooling the bulk
tape to reduce the
temperature is provided after the pressure-sensitive adhesive layer formation
step and the
temperature of the bulk tape is reduced to about room temperature. Examples of
the
temperature control (cool) means used for the cooling step include a method of
bringing the bulk
tape into contact with a water cooled roll at a low temperature, a method of
applying an air flow
at a low temperature to the bulk tape, and a method of winding the bulk tape
onto a roll and then
leaving the bulk tape standing at room temperature for a predetermined period
of time for
cooling (allowing the bulk tape to cool). The production method may further
include an aging
step for an aging period under a certain condition (40 C to 50 C, one day to
two weeks) before
and after the cooling step. Through the aging step, the bulk tape obtains
increased cohesiveness
to achieve stable adhesive power.
Using the bulk tape that is allowed to cool to about room temperature and, if
possible, left
at room temperature for several days as above, the rivastigmine layer
formation step and the
transdermal patch formation step are performed in another working environment
equipped with
an air conditioning apparatus capable of setting the environment at a low
temperature (preferably
20 C to 34 C and more preferably 26 C to 34 C). In the transdermal patch
formation step, the
temperature of the bulk tape may be controlled at, for example, 10 C to 40 C,
preferably 20 C to
34 C, and more preferably 26 C to 34 C, using the temperature control means.
The
temperature in each step can be ascertained by means such as a contact
thermometer, a
non-contact room thermometer, and an infrared thermo sensor.
In this manner, by controlling the temperature of the bulk tape and each
temperature in the
rivastigmine layer formation step and the transdermal patch formation step,
the lamination of the
CA 02865715 2014-08-27
22
bulk tape and the rivastigmine layer is smoothly performed and the two layers
are readily
integrated. However, it should be noted that when the lamination is performed
at room
temperature or below (less than 20 C), the produced transdermal patch may be
separated into
two layers when such a transdermal patch is applied onto a skin and the
pressure-sensitive
adhesive layer is likely to remain on a skin side.
In the production method, the pressure-sensitive adhesive layer formation step
and the
rivastigmine layer formation step are not performed at the same time, and the
transdermal patch
formation step is performed a predetermined time after the pressure-sensitive
adhesive layer
formation step. This facilitates the control of the temperature in each
working environment as
well as can diversify or reduce the risk when malfunction occurs in the steps.
[0038] By bringing the pressure-sensitive adhesive layer into contact
with the
rivastigmine-containing layer, the rivastigmine serving as the active
component is permeated and
diffused from the rivastigmine-containing layer into the pressure-sensitive
adhesive layer. Thus,
a transdermal patch is obtained that includes two layers composed of the
rivastigmine layer and
the pressure-sensitive adhesive layer in which the active component is
substantially equally
contained. For example, with respect to a pressure-sensitive adhesive layer
having a thickness
of 10 vim to 100 vim, the rivastigmine-containing layer is brought into
contact by coating or
lamination to produce a transdermal patch. Then, the transdermal patch is
subjected to aging
under a low temperature condition (1 C or more and less than 50 C) for a day
to about two
weeks. Thus, the transdermal patch having the pressure-sensitive adhesive
layer in which the
rivastigmine is evenly diffused and permeated can be obtained.
[0039] It is preferred that the transdermal patch of the present
invention produced as
above is enclosed in a package prepared from a packing material having high
sealing
performance and high light blocking performance and stored until immediately
before the use.
For the packing material having high sealing performance and high light
blocking
performance used for the package, a material commonly used for the package of
a transdermal
CA 02865715 2014-08-27
23
patch can be used. Examples of the packing material having high sealing
performance include
polyolefin resin films such as polyethylene films, polypropylene films, and
polymethylpentene
films; vinyl resin films such as polyvinyl chloride films, polyvinylidene
chloride films, polyvinyl
alcohol films, polystyrene films,,polyacrylonitrile films, and ionomer films;
polyester resin films
such as polyethylene terephthalate films; polyamide resin films such as nylon
films; cellulose
resin films such as cellophane; polycarbonate resin films; and lamination
films of them.
Examples of the packing material having high light blocking performance in
addition to the high
sealing performance include: lamination films of aluminum and the resin film
above or a
lamination film of the resin films; and pigment-added resin films that is
obtained by adding a
black pigment, for example, to the resin film above. These resin films,
lamination films, and
the like may be used in various combinations as a laminate.
The transdermal patch is enclosed in the package prepared from the laminate,
then the
package can be sealed for storage by a known method such as heat sealing.
[0040] In
particular, the innermost layer of the package is preferably a layer having no
adsorptive property with respect to the rivastigmine. For example,
polyacrylonitrile is
preferably used as the innermost layer.
The package preferably has a film or a sheet that includes a layer containing
an oxygen
adsorber from the viewpoint of the stability of the rivastigmine. Examples of
the oxygen
absorber include, but are not necessarily limited to, inorganic oxides such as
cesium oxide, zinc
oxide, titanium dioxide, and iron oxide; mixtures composed of a powder of iron
such as iron and
iron carbide and an electrolyte such as halogenated metal salts; reducing
inorganic salts such as
sulfite salts, thiosulfate salts, and ferrous salts; polyphenols such as
hydroquinone, catechol,
resorcin, and pyrogallol; reducing sugars such as glucose; any composition
containing a reducing
agent including reducing higher alcohols such as ascorbic acid and erythorbic
acid as a main
active component; compositions containing an unsaturated organic compound such
as
unsaturated fatty acid compounds and chain hydrocarbon polymers having an
unsaturated group
CA 02865715 2014-08-27
24
or a thermoplastic polymer such as polyamides and polyolefins as a main
component and
containing an oxygen absorption promoting substance such as transition-metal
salts; and
mixtures of them. Examples of the packing material containing an oxygen
absorber include
Oxyguard (registered trademark) (manufactured by Toyo Seikan Kaisha, Ltd.) and
OxyCatch
(registered trademark) (manufactured by Kyodo Printing Co., Ltd.). The oxygen
absorber may
be separately enclosed in a package as well as contained in the package (in a
packing material).
It is particularly preferable that an atmosphere in the package be substituted
and filled with
nitrogen with a vacuum gas packaging machine or the like after the transdermal
patch is enclosed
in the package, from the viewpoint of the stability of the rivastigmine.
[0041] The transdermal patch of the present invention obtained as above
has an
advantage of excellent temporal stability of the rivastigmine. For example,
the transdermal
patch of the present invention includes degradation products of the
rivastigmine in a total amount
of less than 0.2% by mass immediately after the production based on the amount
of the
rivastigmine, and includes the degradation products in a total amount of less
than 0.50% by mass
and preferably less than 0.35% by mass after storage under a severe condition
(60 C) for two
weeks based on the amount of the rivastigmine.
Examples
[0042] Hereinafter, the present invention will be described in further
detail with
reference to examples; however, the present invention is not limited to these
examples.
[0043] <Production of Transdermal Patch (1)>
[Example 1: Production of Transdermal Patch by Ointment Coating Method (1)]
At room temperature, 40% by mass of DURO-TAK (registered trademark) 87-2516
(containing a hydroxy group, Henkel) as an acrylic pressure-sensitive adhesive
and 60% of ethyl
acetate were mixed to prepare an acrylic pressure-sensitive adhesive solution
(the value (%) is
based on the total mass of the pressure-sensitive adhesive solution). Next,
the solution was
CA 02865715 2014-08-27
applied onto a silicone release-treated PET film (FILMBYNA (registered
trademark) 75E-0010
No. 23, manufactured by Fujimori Kogyo Co., Ltd.) having a thickness of 75
i.t.m so as to give a
thickness of 80 1.1M after drying, and the coated film was dried at 60 C to
100 C to form a
pressure-sensitive adhesive layer.
Each of 90% by mass of rivastigmine and 10% by mass of Eudragit (registered
trademark)
EPO (Evonik Degussa) was weighed, charged in a glass bottle, and dissolved at
room
temperature so that a rivastigmine solution (the value (%) is based on the
total mass of the
rivastigmine solution) was obtained. The obtained rivastigmine solution was
applied onto a
PET film (LUMIRROR (registered trademark) S10, manufactured by Toray
Industries Inc.)
having a thickness of 25 i_tm as a backing so as to give a thickness of 20 vim
to form a
rivastigmine-containing layer.
The pressure-sensitive adhesive layer formed on the silicone release-treated
PET film and
the rivastigmine-containing layer formed on the PET film were opposed and
laminated to each
other to produce a transdermal patch having two layers of the pressure-
sensitive adhesive layer
containing the acrylic pressure-sensitive adhesive and the rivastigmine-
containing layer.
The produced preparation was sealed in an aluminum package having the
innermost layer
mainly composed of polyacrylonitrile, and nitrogen substitution in the package
was carried out
using a vacuum gas packaging machine.
[0044] [Comparative Example 1: Production of Transdermal Patch by
Ointment
Coating Method (2)]
A transdermal patch was produced in the same manner as in Example 1 except
that
DURO-TAK (registered trademark) 87-2194 (containing a carboxy group, Henkel)
was used as
an acrylic pressure-sensitive adhesive in place of DURO-TAK (registered
trademark) 87-2516
(Henkel) and the pressure-sensitive adhesive layer had a thickness of 60 [tm
after drying.
[0045] [Comparative Example 2: Production of Transdermal Patch by
Ointment
Coating Method (3)]
CA 02865715 2014-08-27
26
A transdermal patch was produced in the same manner as in Example 1 except
that
DURO-TAK (registered trademark) 87-2516 (containing a hydroxy group, Henkel)
and
DURO-TAK (registered trademark) 87-2194 (containing a carboxy group, Henkel)
were used in
combination in equivalent amounts as acrylic pressure-sensitive adhesives in
place of
DURO-TAK (registered trademark) 87-2516 (Henkel) alone and the pressure-
sensitive adhesive
layer had a thickness of 60 m after drying.
[0046] [Comparative Example 3: Production of Transdermal Patch by Spread
Coating
Method (1)]
In accordance with the formulation of 75.0% by mass of DURO-TAK (registered
trademark) 87-2516 (containing a hydroxy group, Henkel) as an acrylic pressure-
sensitive
adhesive, 2.5% by mass of Eudragit (registered trademark) EPO, and 22.5% by
mass of
rivastigmine (the value (%) is based on the total mass of the pressure-
sensitive adhesive layer),
the components were mixed, and diluted with ethyl acetate so as to give a
solid content of 35%
to 40%, and the mixture was stirred at room temperature (about 25 C) to
prepare a homogeneous
pressure-sensitive adhesive solution.
Next, the pressure-sensitive adhesive solution was spread on a silicone
release-treated PET
film (FILMBYNA (registered trademark) 75E-0010 No. 23, manufactured by
Fujimori Kogyo
Co., Ltd.) having a thickness of 75 lam so as to give a thickness of 80 1.1m
after drying, and the
coated film was dried at 60 C to 100 C to form a pressure-sensitive adhesive
layer. Onto the
pressure-sensitive adhesive layer, a PET film (LUMIRROR (registered trademark)
S10,
manufactured by Toray Industries Inc.) having a thickness of 25 1,un was
laminated as a backing
to produce a transdermal patch. The transdermal patch includes one layer of
the
pressure-sensitive adhesive layer containing the acrylic pressure-sensitive
adhesive and the
rivastigmine between the backing and the release liner.
The produced preparation was sealed in an aluminum package having the
innermost layer
mainly composed of polyacrylonitrile, and nitrogen substitution in the package
was carried out
CA 02865715 2014-08-27
27
using a vacuum gas packaging machine.
[0047] [Comparative Example 4: Production of Transdermal Patch by Spread
Coating
Method (2)]
A transdermal patch was produced in the same manner as in Comparative Example
3
except that DURO-TAK (registered trademark) 87-2194 (containing a carboxy
group, Henkel)
was used as an acrylic pressure-sensitive adhesive in place of DURO-TAK
(registered
trademark) 87-2516 (Henkel). The transdermal patch includes one layer of the
pressure-sensitive adhesive layer containing the acrylic pressure-sensitive
adhesive and the
rivastigmine between the backing and the release liner.
[0048] [Comparative Example 5: Production of Transdermal Patch by Spread
Coating
Method (3)]
A transdermal patch was produced in the same manner as in Comparative Example
3
except that DURO-TAK (registered trademark) 87-2516 (containing a hydroxy
group, Henkel)
and Durotak 87-2194 (containing a carboxy group, Henkel) were used in
combination in
equivalent amounts as acrylic pressure-sensitive adhesives in place of DURO-
TAK (registered
trademark) 87-2516 (Henkel) alone. The transdermal patch includes one layer of
the
pressure-sensitive adhesive layer containing the acrylic pressure-sensitive
adhesive and the
rivastigmine between the backing and the release liner.
[0049] <Stability Evaluation of Transdermal Patch (1)>
(1) Amount of Degradation Product Contained Immediately After Production of
Transdermal
Patch
The total amount (% by mass) of degradation products contained was measured
immediately after the production in accordance with the following procedure,
in each
transdermal patch produced in Example 1 and Comparative Example 1 to
Comparative Example
5.
The obtained results are shown in Table 1.
CA 02865715 2014-08-27
28
[Measurement Procedure for Amount of Degradation Product Contained]
The measurement method of the amount of degradation products contained was as
follows.
That is, the release liner of the transdermal patch was removed; the
transdermal patch was
immersed in a sealable glass container containing tetrahydrofuran to dissolve
the
pressure-sensitive adhesive; then purified water was added to the solution;
and the diluted
solution was analyzed by high performance liquid chromatography (HPLC). The
amount of
degradation products contained was determined in accordance with the formula
below. The
peak area of each degradation product was calculated with respect to the peak
area of the
rivastigmine, and the total sum of the peak areas of the degradation products
was calculated as
the total amount (%) of the degradation products.
Amount of degradation products contained (%) = [peak area of degradation
products/peak
area of rivastigmine] x 100
[0050] Table 1
Pressure-sensitive Containing OH group Containing COOH group
Containing OH group/COOH
adhesive group
Coating method Ointment Spread Ointment Spread
Ointment Spread coating
coating coating coating coating coating
Transdermal Example Comparative Comparative Comparative Comparative
Comparative
patch No. 1 Example 3 Example 1 Example 4 Example 2
Example 5
Total amount of 0.191 0.783 0.126 0.310 0.146 0.439
degradation
products *
* Each value represents an amount in terms of A, by mass with respect to
rivastigmine.
[0051] As shown in Table 1, in each transdermal patch using the acrylic
pressure-sensitive adhesive containing a hydroxy group, the acrylic pressure-
sensitive adhesive
containing a carboxy group, or the acrylic pressure-sensitive adhesives
containing a hydroxy
group and a carboxy group, the obtained results revealed that each transdermal
patch (Example 1,
Comparative Example 1, and Comparative Example 2) produced by the ointment
coating method
contained the degradation products in a very small amount, as compared with
that of each
transdermal patch (Comparative Example 3, Comparative Example 4, and
Comparative Example
5) produced by the spread coating method.
CA 02865715 2014-08-27
29
[0052] (2) Change in Total Amount of Degradation Products after Storage
of
Transdermal Patch under Severe Condition (1)
The total amount of degradation products was measured after the storage under
a severe
condition (60 C) for a week and two weeks in accordance with [Measurement
Procedure for
Amount of Degradation Product Contained] above, in each transdermal patch
produced in
Example 1, Comparative Example 1, Comparative Example 3, and Comparative
Example 4.
The obtained results are shown in Table 2 and Table 3.
[0053] Table 2
Pressure-sensitive Acrylic pressure-sensitive adhesive containing OH group
adhesive
Transdermal patch Example 1/ointment coating Comparative Example
3/spread coating
No./coating method
Time course Immediately After a After two Immediately
After a After two
after week weeks after week weeks
production production
Total amount of 0.191 0.280 0.345 0.783 0.946 , 1.104
degradation products *
Change in amount 0.0772 0.1607
(slope) **
* Each value represents an amount in terms of A by mass with respect to
rivastigmine.
** The slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course
Table 3
Pressure-sensitive Acrylic pressure-sensitive adhesive containing COOH
group
adhesive
Transdermal patch Comparative Example 1/ointment coating Comparative
Example 4/spread coating
No./coating method
Time course Immediately After a After two Immediately
After a After two
after week weeks after week weeks
production production
Total amount of 0.126 0.454 0.682 0.310 0.776 1.388
degradation products *
Change in amount 0.2780 0.5389
(slope) **
* Each value represents an amount in terms of % by mass with respect to
rivastigmine.
** The slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course
CA 02865715 2014-08-27
[0054] As shown in Table 2 and Table 3, in each transdermal patch using
the acrylic
pressure-sensitive adhesive containing a hydroxy group or the acrylic pressure-
sensitive adhesive
containing a carboxy group, the obtained results revealed that each
transdermal patch (Example 1
and Comparative Example 1) produced by the ointment coating method contained
the
degradation products in a very small amount, as compared with that of each
transdermal patch
(Comparative Example 3 and Comparative Example 4) produced by the spread
coating method
after the storage for two weeks.
In the transdermal patches produced by the ointment coating method, the
obtained results
revealed that the transdermal patch (Example 1) using the acrylic pressure-
sensitive adhesive
containing a hydroxy group contained the degradation products in an amount
smaller than that of
the transdermal patch (Comparative Example 1) using the acrylic pressure-
sensitive adhesive
containing a carboxy group after the storage for two weeks.
The changes with time in the total amount of degradation products contained
were
compared as the slope of an approximate line determined from plots of the
total amount of
degradation products with respect to the time course. The obtained results
revealed that the
transdermal patch using the hydroxy-containing acrylic pressure-sensitive
adhesive and produced
by the ointment coating method had the smallest slope, that is, had the
smallest change with time
in the total amount of degradation products and had high stability.
[0055] <Production of Transdermal Patch (2)>
[Example 2]
A transdermal patch was produced in the same manner as in Example 1 except
that the
pressure-sensitive adhesive layer had a thickness of 60 m.
[0056] [Example 3]
A transdermal patch was produced in the same manner as in Example 1 except
that
DURO-TAK (registered trademark) 87-2287 (containing a hydroxy group, Henkel)
was used as
an acrylic pressure-sensitive adhesive in place of DURO-TAK (registered
trademark) 87-2516
CA 02865715 2014-08-27
31
(Henkel) and the pressure-sensitive adhesive layer had a thickness of 601,1m.
[0057] [Comparative Example 6]
A transdermal patch was produced in the same manner as in Example 1 except
that
MAS683 (acrylic pressure-sensitive adhesive containing a pyrrolidone ring,
CosMED
Pharmaceutical Co. Ltd.) was used as an acrylic pressure-sensitive adhesive in
place of
DURO-TAK (registered trademark) 87-2516 (Henkel) and the pressure-sensitive
adhesive layer
had a thickness of 60 tn.
[0058] [Comparative Example 7: Commercial Product]
In Comparative Example 7, RIVASTACH (registered trademark) Patch 18 mg
(manufactured by Ono Pharmaceutical Co., Ltd.) that is a commercially
available transdermal
patch containing the rivastigmine was used.
[0059] <Stability Evaluation of Transdermal Patch (2)>
(3) Change in Total Amount of Degradation Products after Storage of
Transdermal Patch under
Severe Condition (2)
The total amount of degradation products contained was measured immediately
after the
production and after the storage under a severe condition (60 C) for a week
and two weeks in
accordance with [Measurement Procedure for Amount of Degradation Product
Contained] above,
in each transdermal patch produced in Example 2, Example 3, Comparative
Example 6, and
Comparative Example 7.
The obtained results are shown in Table 4 and Table 5.
CA 02865715 2014-08-27
32
[0060] Table 4
Pressure-sensitive Acrylic pressure-sensitive adhesive containing OH group
adhesive
Transdermal Example 1 (shown again) Example 2 Example
3
patch No.
Time course Immediate 1 2 Immediate 1 2 Immediate 1 2
week weeks week weeks
week weeks
Total amount of 0.191 0.280 0.345 0.145 0.324 0.288
0.142 0.218 0.229
degradation
products *
Change in 0.0772 0.0717 0.0432
amount (slope)
**
* Each value represents an amount in terms of % by mass with respect to
rivastigmine.
** The slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course
Table 5
Pressure- Acrylic pressure-sensitive
Pyrrolidone pressure-sensitive Commercial product: RIVASTACH
sensitive adhesive containing COOH adhesive
adhesive group
Transder Comparative Example 1 Comparative Example 6 Comparative Example
7
mal patch (shown again)
No.
Time Immediate 1 2 Immediate 1 2 weeks Immediate 1 week 2
weeks
course week weeks week
Total 0.126 0.454 0.682 0.550 0.722 0.722 0.169 0.322 0.376
amount
of
degradati
on
products
Change 0.2780 0.0858 0.1033
in
amount
(slope)
**
* Each value represents an amount in terms of % by mass with respect to
rivastigmine.
** The slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course
CA 02865715 2014-08-27
33
[0061] As shown in Table 4 and Table 5, the obtained results revealed
that each
transdermal patch (Example 1 to Example 3) using the acrylic pressure-
sensitive adhesive
containing a hydroxy group contained the degradation products in an amount
(total amount)
smaller than those of each transdermal patch (Comparative Example 1 and
Comparative
Example 6) using a pressure-sensitive adhesive other than the acrylic pressure-
sensitive adhesive
containing a hydroxy group and of the commercially available transdermal patch
(Comparative
Example 7) after the storage for two weeks.
Also in the change with time in the total amount of degradation products
contained that was
calculated as the slope of an approximate line determined from plots of the
total amount of
degradation products with respect to the time course, the obtained results
revealed that each
transdermal patch (Example 1 to Example 3) using the acrylic pressure-
sensitive adhesive
containing a hydroxy group had a slope smaller than those of the other
transdermal patches and
had high stability.
[0062] <Performance Evaluation of Transdermal Patch>
Using each transdermal patch of Example 1 and Comparative Example 3, the
holding force
to a glass plate and the probe tack were measured in accordance with the
following procedures.
[0063] (1) Holding Power With Respect To Glass Plate
The measurement of holding power with respect to a glass plate was carried out
in
accordance with JIS Z-0237. A sample having a width of 12 mm was laminated to
a glass plate
so as to give an area of 12 mm x 20 mm at a temperature of 23 C in an
atmosphere of 50% RH,
and was pressed for laminating by one set of reciprocal movement of a 2-kg
rubber roller at a
speed of 300 mm/min. After the sample was left standing for 20 minutes, the
pressure-sensitive
adhesive sheet was vertically hung, then a load of 100 g was applied to the
sheet, and the
displaced length was measured after 15 minutes and 30 minutes. The obtained
results are
shown in Table 6.
[0064] (2) Probe Tack
The measurement of probe tack was carried out in accordance with Reference 5
in JIS
CA 02865715 2014-08-27
34
Z-0237 (1991). Using a probe tack tester from Nichiban, a smooth leading end
face of a metal
cylindrical probe having a diameter of 5 mm was laminated to a surface of a
pressure-sensitive
adhesive at a temperature of 23 C in an atmosphere of 50% RH while applying a
load of 0.98
N/cm2 (100 1 gf/cm2) for 1.0 0.1 second, and the resistance value was
measured when the
probe was peeled at 10 0.1 mm per second. The obtained results are shown in
Table 6.
[0065] Table 6
Pressure-sensitive adhesive Acrylic pressure-sensitive adhesive
containing OH group
Coating method Ointment coating Spread coating
Transdermal patch No. Example 1 Comparative Example 3
Holding power with respect to After 15 0.9 2.1
glass plate (mm/12 x 20 mm, minutes
load 100 g) After 30 2.1 Fallen
minutes
Probe tack (N/5 mm CD) 5.54 5.10
[0066] As shown in Table 6, the obtained results revealed that the
transdermal patch of
Example 1 produced by the ointment coating method had a holding power with
respect to a glass
plate and a probe tack which are both better than those of the transdermal
patch of Comparative
Example 3 produced by the solvent coating method.
[0067] <Production of Transdermal Patch (3)>
[Example 4]
A transdermal patch was produced in the same manner as in Example 1 except
that
DURO-TAK (registered trademark) 87-2287 (containing a hydroxy group, Henkel)
was used as
an acrylic pressure-sensitive adhesive in place of DURO-TAK (registered
trademark) 87-2516
(Henkel), the pressure-sensitive adhesive layer had a thickness of 60 pm, and
the nitrogen
substitution was not performed after the sealing of the produced preparation
in a package.
[0068] [Comparative Example 8]
A transdermal patch was produced in the same manner as in Example 1 except
that
MAS683 (acrylic pressure-sensitive adhesive containing a pyrrolidone ring,
CosMED
Pharmaceutical Co. Ltd.)) was used as an acrylic pressure-sensitive adhesive
in place of
DURO-TAK (registered trademark) 87-2516 (Henkel), the pressure-sensitive
adhesive layer had
a thickness of 60 pm, and the nitrogen substitution was not performed after
the sealing of the
CA 02865715 2014-08-27
produced preparation in a package.
[0069] <Stability Evaluation of Transdermal Patch (3)>
(4) Change in Total Amount of Degradation Products after Storage of
Transdermal Patch under
Severe Condition (3)
The total amount of degradation products was measured in accordance with
[Measurement
Procedure for Amount of Degradation Product Contained] above immediately after
the
production and after the storage under a severe condition (60 C) for two
weeks, in each
transdermal patch produced in Example 4 and Comparative Example 8.
The obtained results are shown in Table 7.
CA 02865715 2014-08-27
36
[0070] Table 7
Pressure Acrylic pressure-sensitive adhesive Pyrrolidone pressure-sensitive
adhesive (reference)
-sensitiv containing OH group RIVASTACH
adhesiv
Transde Example 3 Example 4 Comparative Comparative Comparative
rmal (shown again) Example 6 (shown Example 8
Example 7
patch again) (shown again)
No.
Nitroge Performed Not performed Performed Not performed -
n
substitut
ion
Time Immediat 2 Immedi 2 Immediate 2
Immediat 2 Immedi 2
course e wee ate wee weeks e wee ate wee
ks ks ks ks
Total 0.142 0.22 0.097 0.4 0.550 0.722 0.716 1.19 0.169 0.37
amount 9 76 5 6
of
degrada
tion
product
s*
Change 0.0432 0.1895 0.0858 0.2395 0.1033
in
amount
(slope)
**
* Each value represents an amount in terms of % by mass with respect to
rivastigmine.
** The slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course
CA 02865715 2014-08-27
37
[0071] As shown in Table 7, the obtained results revealed that by
sealing the produced
preparation in the aluminum package having the innermost layer mainly composed
of
polyacrylonitrile, and then performing the nitrogen substitution in the
package using a vacuum
gas packaging machine, it is possible to provide a transdermal patch having a
smaller amount
(total amount) of degradation products contained after the storage for two
weeks, having a
smaller change with time in the total amount of degradation products contained
that is calculated
as the slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course, and having higher stability.
[0072] <Production of Transdermal Patch (4)>
[0073] [Example 5]
A transdermal patch was produced in the same manner as in Example 1 except
that
DURO-TAK (registered trademark) 87-2516 (containing a hydroxy group, Henkel)
and
DURO-TAK (registered trademark) 87-2287 (containing a hydroxy group, Henkel)
were used in
combination in equivalent amounts as acrylic pressure-sensitive adhesives in
place of
DURO-TAK (registered trademark) 87-2516 (Henkel) alone and the produced
preparation was
sealed in OxyCatch (registered trademark) (manufactured by Kyodo Printing Co.,
Ltd.) as a
package containing an oxygen absorber in place of the aluminum package having
the innermost
layer mainly composed of polyacrylonitrile.
[0074] <Stability Evaluation of Transdermal Patch (4)>
(5) Change in Total Amount of Degradation Products after Storage of
Transdermal Patch under
Severe Condition (4)
The total amount of degradation products was measured in accordance with
[Measurement
Procedure for Amount of Degradation Product Contained] above immediately after
the
production and after the storage under a severe condition (60 C) for a week,
in the transdermal
patch produced in Example 5.
The obtained results are shown in Table 8.
CA 02865715 2014-08-27
38
[0075] Table 8
Pressure-sensitive adhesive Acrylic pressure-sensitive
(reference) RIVASTACH
adhesive containing OH group
Transdermal patch No. Example 5 Comparative Example 7
(shown again)
Time course Immediate 1 week Immediate 1 week
Total amount of degradation 0.185 0.273 0.169
0.322
products *
Change in amount (slope) ** 0.0880 0.1033
* Each value represents an amount in terms of % by mass with respect to
rivastigmine.
** The slope of an approximate line determined from plots of the total amount
of degradation
products with respect to the time course
[0076] As shown in Table 8, the obtained results revealed that the
sealing of the
produced preparation in the package containing the oxygen absorber in place of
the aluminum
package having the innermost layer mainly composed of polyacrylonitrile can
produce the
transdermal patch having further improved stability.
